You just read:

Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015

News provided by

CTI BioPharma Corp. , Baxter

May 30, 2015, 07:30 ET